Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
Last trade$6.21
Day change-$0.19 (-2.97%)
Day range$5.98 – $6.81
Volume63,879
Market cap$65M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$65.21M
Price / earnings
—
Price / book
-1.72×
Price / sales
16.45×
EV / sales
15.42×
EV / EBITDA
-4.52×
Profitability
Earnings per share
-$1.43
Return on assets
-78.54%
Return on equity
38.56%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0×
Current ratio
1.72×
Quick ratio
1.72×
Cash ratio
0.62×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.99M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ATRA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.22M
$630K
$516K
$1.6M
$3.45M
$17.58M
$98.15M
$32.75M
Cost of revenue
$265K
$191K
$124K
$104K
$115K
$554K
$20.44M
$6.8M
Gross profit
$959K
$439K
$392K
$1.49M
$3.34M
$17.02M
$77.71M
$25.96M
Selling, general and administrative
$2.83M
$3.81M
$3.6M
$4.28M
$3.99M
$6.51M
$11.48M
$9.44M
Research and development
$1.1M
$1.35M
$164K
-$223K
$2.93M
$7.31M
$27.43M
$28.72M
Total operating expenses
$3.93M
$5.16M
$3.76M
$4.05M
$6.91M
$13.82M
$38.91M
$38.16M
Operating income
-$2.97M
-$4.72M
-$3.37M
-$2.56M
-$3.57M
$3.2M
$38.8M
-$12.2M
Interest expense
$682K
-$191K
-$830K
-$894K
-$906K
-$972K
-$1.02M
-$1.02M
Income before taxes
-$2.23M
-$4.83M
-$4.15M
-$3.41M
-$4.28M
$2.39M
$38.01M
-$12.71M
Income taxes
$0
$1K
$0
$0
$28K
$3K
$0
-$19K
Net income
-$2.23M
-$4.83M
-$4.15M
-$3.41M
-$4.3M
$2.39M
$38.01M
-$12.69M
Net income attributable to common shareholders
-$2.23M
-$4.83M
-$4.15M
-$3.41M
-$4.3M
$2.39M
$38.01M
-$12.69M
EBITDA
-$2.97M
-$4.71M
-$3.34M
-$2.51M
-$3.54M
$3.43M
$40.6M
-$11.1M
Basic earnings per share
-$0.15
-$0.32
-$0.29
-$0.25
-$0.32
$0.20
$3.53
-$1.18
Diluted earnings per share
-$0.15
-$0.32
-$0.29
-$0.24
-$0.32
$0.19
$3.50
-$1.18
Recent news
Company coverage with links to the original publishers.
A securities class action lawsuit has been filed against Atara Biotherapeutics for allegedly making false and misleading statements regarding manufacturing issues and deficiencies in the ALLELE study that undermined FDA approval prospects for tabelecleucel. Investors who purchased securities between May 20, 2024 and January 9, 2026 may be eligible for compensation. The lead plaintiff deadline is May 22, 2026.
A class action lawsuit has been filed against Atara Biotherapeutics, Inc. alleging that company executives made false and misleading statements regarding manufacturing issues and deficiencies in the ALLELE study that would likely prevent FDA approval of tabelecleucel. The lawsuit covers investors who purchased Atara securities between May 20, 2024 and January 9, 2026.
Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Atara Biotherapeutics (ATRA), Coty Inc. (COTY), Super Micro Computer (SMCI), and ImmunityBio (IBRX). The lawsuits allege that defendants made false or misleading statements regarding their business operations and prospects. Lead plaintiff deadlines range from May 22-26, 2026.
A class action lawsuit has been filed against Atara Biotherapeutics, Inc. alleging that company executives made false and misleading statements regarding manufacturing issues and deficiencies in the ALLELE study that would likely prevent FDA approval of tabelecleucel. The lawsuit covers investors who purchased Atara securities between May 20, 2024 and January 9, 2026. The lead plaintiff deadline is May 22, 2026.
The Schall Law Firm is seeking investors to join a class action lawsuit against Atara Biotherapeutics for alleged securities fraud. The company allegedly made false and misleading statements regarding manufacturing problems and deficiencies in its ALLELE study for tabelecleucel, overstating the drug's prospects and concealing regulatory risks. Investors who purchased securities between May 20, 2024 and January 9, 2026 are encouraged to participate.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.